The peptide reference catalog,
built for research transparency.

Long-acting GLP-1 receptor agonist for glycemic control and weight management.

The once-daily GLP-1 agonist that preceded semaglutide — FDA-approved for diabetes (Victoza) and obesity (Saxenda).

Dual GIP / GLP-1 receptor agonist with industry-leading weight-loss endpoints.

Investigational triple agonist (GIP / GLP-1 / glucagon) in late-stage trials.

Investigational glucagon / GLP-1 dual agonist from Boehringer Ingelheim — Phase 3 for obesity and MASH.

A glucagon / GLP-1 dual agonist (oxyntomodulin-based) approved in China for weight management and diabetes — not yet FDA-approved.

Long-acting amylin analog studied alongside semaglutide as CagriSema.

Novo Nordisk’s investigational fixed combination of cagrilintide (amylin) and semaglutide (GLP-1) — two appetite pathways in one weekly injection.

Synthetic gastric pentadecapeptide investigated for tendon, ligament, and GI repair.

Synthetic fragment of thymosin β4 studied for cell migration and tissue repair.

A 27-residue single-chain relaxin-2 analog and selective RXFP1 agonist — a simplified relaxin mimetic studied for anti-fibrotic effects.

Endogenous copper-binding tripeptide widely studied in skin and hair biology.

Copper-binding tripeptide (Ala-His-Lys) studied for hair-follicle stimulation and dermal repair.

A topical "neurocosmetic" hexapeptide that mimics SNAP-25 to soften expression wrinkles — often called topical Botox.

An elongated, higher-potency relative of Argireline — an eight-residue SNAP-25 mimic used as a topical, needle-free anti-wrinkle peptide.

A glycoprotein hormone that drives red-blood-cell production — a recombinant biologic famous in medicine for treating anemia and infamous in sport for blood doping.

An 11-amino-acid, non-erythropoietic fragment of erythropoietin that keeps EPO’s tissue-protective, anti-inflammatory activity without raising red blood cells.

The active fragment of parathyroid hormone — a recombinant peptide that builds bone, exploiting a paradox: the same hormone resorbs bone when continuous, but builds it when pulsed.

Recombinant 191-amino-acid human growth hormone — a folded protein biologic identical in sequence to pituitary GH, not a synthetic research peptide.

The downstream effector of growth hormone — a 70-amino-acid recombinant protein, structurally a cousin of proinsulin, that carries out most of GH’s growth signal.

A long-acting modified IGF-1 analog with reduced IGFBP binding and prolonged systemic activity.

A truncated IGF-1 missing its first three residues — sharply reduced IGFBP binding and high local potency, but short-acting.

A splice variant of IGF-1 expressed after muscle damage; studied for satellite-cell activation.

Modified GHRH(1-29) analog with short plasma half-life.

Long-acting GHRH analog with a Drug Affinity Complex for albumin binding.

Selective ghrelin receptor agonist (GHRP) with minimal cortisol / prolactin release.

GHRH analog FDA-approved for HIV-associated lipodystrophy.

Truncated GHRH(1-29) — historically the first GHRH analog approved by the FDA.

Synthetic hexapeptide GHRP with potent GH-releasing activity.

Second-generation synthetic GHRP; a potent ghrelin-receptor agonist approved in Japan as a diagnostic for GH deficiency.

The original growth-hormone-releasing peptide — the tool compound that led scientists to the ghrelin receptor and, ultimately, to ghrelin itself.

An orally active, non-peptide ghrelin-receptor agonist and growth-hormone secretagogue — a small molecule catalogued alongside the GH peptides.

The body’s brake on muscle growth — a TGF-β-family growth factor whose inhibition is the leading strategy to preserve muscle, including during GLP-1 weight loss.

A natural myostatin and activin antagonist — by neutralizing the muscle brake it is one of the most potent pro-muscle factors studied, and a doping and gene-therapy flashpoint.

An anti-myostatin antibody (Regeneron) now studied in obesity combinations to cut lean-mass loss and deepen fat loss alongside semaglutide.

An anti-activin-A antibody (Regeneron) — closest to approval of the axis (FOP), and a partner in obesity muscle-preservation combinations.

Mitochondrially-encoded peptide with reported insulin-sensitizing activity.

A 24-amino-acid mitochondrial-derived peptide with cytoprotective, anti-apoptotic activity — a companion to MOTS-c on the mitochondrial-signaling frontier.

Mitochondria-targeted cardiolipin-binding tetrapeptide.

Synthetic tetrapeptide investigated for telomerase activity and circadian effects.

The natural pineal peptide bioregulator — the animal-derived counterpart to synthetic Epitalon, marketed for aging and telomere support.

A senolytic D-retro-inverso peptide that selectively triggers apoptosis in senescent cells by disrupting the FOXO4–p53 interaction.

Thymus-derived polypeptide complex — the founding tissue bioregulator (Cytomax) studied for immune restoration.

A synthetic thymic dipeptide (Glu-Trp) immunomodulator — the minimal active fragment distilled from thymus peptides.

Synthetic Lys-Glu dipeptide — the defined short-peptide successor to Thymalin, studied for immune and aging endpoints.

Synthetic Lys-Glu-Asp tripeptide studied as a vascular-axis bioregulator.

Synthetic Glu-Asp-Arg tripeptide studied as a brain/CNS bioregulator.

Synthetic Ala-Asp-Glu-Leu tetrapeptide studied as a respiratory-tissue bioregulator.

Synthetic Ala-Glu-Asp-Arg tetrapeptide studied as a cardiac-tissue bioregulator.

Synthetic Lys-Glu-Asp-Trp tetrapeptide studied as a pancreas-tissue bioregulator.

Synthetic Lys-Glu-Asp-Gly tetrapeptide studied as a testis / reproductive-tissue bioregulator.

Synthetic Lys-Glu-Asp-Pro tetrapeptide studied as a prostate-tissue bioregulator — the defined-sequence successor to older prostate extracts.

A natural thymus peptide complex (Cytomax A-6) — the extract-based counterpart to Thymalin, marketed for immune support and aging.

A natural blood-vessel peptide complex (Cytomax A-3) — the extract-based counterpart to Vesugen, targeting vascular tissue.

A natural heart-muscle peptide complex (Cytomax A-14) — the extract-based counterpart to Cardiogen, targeting cardiac tissue.

Russian synthetic ACTH(4-10) analog studied for nootropic and neuroprotective effects.

Synthetic heptapeptide analog of tuftsin investigated as an anxiolytic.

Endogenous nonapeptide first isolated for its sleep-promoting properties.

A porcine-brain-derived mixture of neuropeptides and free amino acids with neurotrophic activity — approved for stroke and dementia outside the US.

An orally active angiotensin IV–derived peptidomimetic reported as an extraordinarily potent synaptogenic (synapse-forming) compound.

Synthetic cyclic analog of α-MSH; non-selective melanocortin receptor agonist.

MC1R-selective α-MSH analog; FDA-approved (Scenesse) for photoprotection in erythropoietic protoporphyria.

Melanocortin-4 receptor agonist FDA-approved for HSDD in premenopausal women.

C-terminal decapeptide fragment of kisspeptin; potent GnRH secretagogue.

Synthetic GnRH — the native decapeptide at the top of the pituitary-gonadal axis; pulsatile dosing switches the axis on, continuous dosing shuts it down.

A heterodimeric glycoprotein hormone — two different glycosylated subunits — that mimics the LH surge; the pregnancy hormone, also the subject of a debunked diet.

A 9-amino-acid cyclic hormone of labor and bonding — historically the first peptide hormone ever chemically synthesized, and the most over-marketed "love hormone."

A heterodimeric glycoprotein gonadotropin that drives follicle growth and spermatogenesis — the workhorse of IVF stimulation, and a sister molecule to HCG and LH.

Thymus-derived 28-amino-acid peptide approved in many countries as an immunomodulator.

Human cathelicidin antimicrobial peptide active across bacteria, fungi, and viruses.

Anti-inflammatory C-terminal tripeptide of α-MSH.

The lipolytic C-terminal fragment of human growth hormone — the parent peptide that AOD-9604 was engineered from.

C-terminal hGH fragment (177–191) historically investigated for lipolysis.

A fat-targeting proapoptotic peptide that destroys the blood supply of white fat — striking in animals, but discontinued in humans for kidney toxicity.

Small-molecule NNMT inhibitor (often catalogued alongside peptides).

Essential redox cofactor central to mitochondrial bioenergetics and sirtuin activity.

The body’s master antioxidant — a tripeptide (γ-Glu-Cys-Gly) sold as an injectable for antioxidant, detox, and skin-related use.

The body’s water-conservation hormone — a 9-amino-acid posterior-pituitary peptide, near-twin of oxytocin, used as a vasopressor and (as desmopressin) for diabetes insipidus.

The universal "off switch" — a cyclic hormone that inhibits growth hormone, insulin, glucagon, and gut secretions; its analog octreotide is the workhorse drug.

A calcium-lowering hormone of the thyroid C-cells — the salmon form, far more potent than human, is used for hypercalcemia, Paget’s disease, and bone pain.

The pancreas’s second satiety hormone — co-secreted with insulin from the beta cell; its stabilized analog pramlintide treats diabetes, and the class now drives a new wave of obesity drugs.

The pituitary’s command to the adrenal gland — a 39-amino-acid hormone that drives cortisol release; its 1–24 fragment is the standard test of adrenal function.

The first hormone ever discovered — the 1902 gut peptide that coined the word "hormone"; today a diagnostic agent for the pancreas.

A 28-amino-acid neuropeptide and gut hormone with broad anti-inflammatory and vasodilatory activity — studied in chronic inflammatory illness and, as aviptadil, in the lung.

The only hormone that makes you hungry — a stomach peptide, uniquely fatty-acid-modified, that drives appetite and also releases growth hormone.